Princeton, New Jersey 08540

  • Parkinson's Disease


This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.

Study summary:

Patients with Parkinson's disease with motor complications on levodopa therapy who completed the prior double-blind studies 6002-EU-007, 6002-US-013 or 6002-US-018 are eligible to enter into this 1-year, long-term open safety study with a starting istradefylline dose of 40mg per day.


Inclusion Criteria: - Completion of study 6002-EU-007, 6002-US-013 or 6002-US-018 - Non-pregnant and either not of childbearing potential or using specified contraception Exclusion Criteria: - History of psychotic illness - Variant/atypical Parkinson's disease - Cancer within 5 years of enrollment - ALT/AST levels > 1.5 times ULN - Seizure disorder - Neuroleptic malignant syndrome



Primary Contact:

Study Director
Neil Sussman, MD
Kyowa Kirin Pharmaceutical Development, Inc.

Backup Contact:


Location Contact:

Princeton, New Jersey 08540
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.